journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://read.qxmd.com/read/31515155/targeting-lineage-plasticity-in-prostate-cancer
#1
Emmanuel S Antonarakis
No abstract text is available yet for this article.
September 9, 2019: Lancet Oncology
https://read.qxmd.com/read/31515154/cabazitaxel-plus-carboplatin-for-the-treatment-of-men-with-metastatic-castration-resistant-prostate-cancers-a-randomised-open-label-phase-1-2-trial
#2
Paul G Corn, Elisabeth I Heath, Amado Zurita, Naveen Ramesh, Lianchun Xiao, Emi Sei, Elsa Li-Ning-Tapia, Shi-Ming Tu, Sumit K Subudhi, Jennifer Wang, Xuemei Wang, Eleni Efstathiou, Timothy C Thompson, Patricia Troncoso, Nicholas Navin, Christopher J Logothetis, Ana M Aparicio
BACKGROUND: Taxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive the greatest benefit from the addition of platinum. We aimed to determine whether adding carboplatin to cabazitaxel would improve the outcomes of men with metastatic castration-resistant prostate cancer. METHODS: We did a phase 1-2, open label, randomised study at two centres in men with progressive metastatic castration-resistant prostate cancer...
September 9, 2019: Lancet Oncology
https://read.qxmd.com/read/31494037/endocrine-treatment-versus-chemotherapy-in-postmenopausal-women-with-hormone-receptor-positive-her2-negative-metastatic-breast-cancer-a-systematic-review-and-network-meta-analysis
#3
Mario Giuliano, Francesco Schettini, Carla Rognoni, Manuela Milani, Guy Jerusalem, Thomas Bachelot, Michelino De Laurentiis, Guglielmo Thomas, Pietro De Placido, Grazia Arpino, Sabino De Placido, Massimo Cristofanilli, Antonio Giordano, Fabio Puglisi, Barbara Pistilli, Aleix Prat, Lucia Del Mastro, Sergio Venturini, Daniele Generali
BACKGROUND: Although international guidelines support the administration of hormone therapies with or without targeted therapies in postmenopausal women with hormone-receptor-positive, HER2-negative metastatic breast cancer, upfront use of chemotherapy remains common even in the absence of visceral crisis. Because first-line or second-line treatments, or both, based on chemotherapy and on hormone therapy have been scarcely investigated in head-to-head randomised controlled trials, we aimed to compare these two different approaches...
September 4, 2019: Lancet Oncology
https://read.qxmd.com/read/31494036/cdk4-6-inhibitors-taking-the-place-of-chemotherapy
#4
Azadeh Nasrazadani, Adam M Brufsky
No abstract text is available yet for this article.
September 4, 2019: Lancet Oncology
https://read.qxmd.com/read/31492632/2019-international-clinical-practice-guidelines-for-the-treatment-and-prophylaxis-of-venous-thromboembolism-in-patients-with-cancer
#5
REVIEW
Dominique Farge, Corinne Frere, Jean M Connors, Cihan Ay, Alok A Khorana, Andres Munoz, Benjamin Brenner, Ajay Kakkar, Hanadi Rafii, Susan Solymoss, Dialina Brilhante, Manuel Monreal, Henri Bounameaux, Ingrid Pabinger, James Douketis
Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy. The International Initiative on Thrombosis and Cancer is an independent academic working group aimed at establishing a global consensus for the treatment and prophylaxis of VTE in patients with cancer. The International Initiative on Thrombosis and Cancer last updated its evidence-based clinical practice guidelines in 2016 with a free, web-based mobile phone application, which was subsequently endorsed by the International Society on Thrombosis and Haemostasis...
September 3, 2019: Lancet Oncology
https://read.qxmd.com/read/31488360/health-related-quality-of-life-and-neurocognitive-functioning-with-lomustine-temozolomide-versus-temozolomide-in-patients-with-newly-diagnosed-mgmt-methylated-glioblastoma-ceteg-noa-09-a-randomised-multicentre-open-label-phase-3-trial
#6
Johannes Weller, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel, Peter Hau, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Oliver Bähr, Martin Uhl, Clemens Seidel, Ghazaleh Tabatabai, Stefanie Brehmer, Lars Bullinger, Norbert Galldiks, Christina Schaub, Sied Kebir, Walter Stummer, Matthias Simon, Rolf Fimmers, Christoph Coch, Martin Glas, Ulrich Herrlinger, Niklas Schäfer
BACKGROUND: The CeTeG/NOA-09 trial showed significantly longer overall survival with combined lomustine-temozolomide therapy compared with standard temozolomide for patients with glioblastoma with methylated MGMT promoter. The trial also aimed to investigate the effect of lomustine-temozolomide therapy on health-related quality of life (HRQOL) and neurocognitive function, which we report here. METHODS: In this randomised, multicentre, open-label, phase 3 trial, newly diagnosed, chemoradiotherapy-naive patients with MGMT-methylated glioblastoma, aged 18-70 years, with a Karnofsky performance score of 70% or higher, were recruited and enrolled at 17 university hospitals in Germany...
September 2, 2019: Lancet Oncology
https://read.qxmd.com/read/31477452/pyrotinib-versus-lapatinib-in-her2-positive-breast-cancer
#7
Elizabeth Gourd
No abstract text is available yet for this article.
August 30, 2019: Lancet Oncology
https://read.qxmd.com/read/31477451/selinexor-dexamethasone-for-refractory-multiple-myeloma
#8
Robert Stirrups
No abstract text is available yet for this article.
August 30, 2019: Lancet Oncology
https://read.qxmd.com/read/31477450/nelfinavir-with-concurrent-chemoradiotherapy-in-nsclc
#9
Manjulika Das
No abstract text is available yet for this article.
August 30, 2019: Lancet Oncology
https://read.qxmd.com/read/31474354/niraparib-plus-bevacizumab-versus-niraparib-alone-for-platinum-sensitive-recurrent-ovarian-cancer-nsgo-avanova2-engot-ov24-a-randomised-phase-2-superiority-trial
#10
Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J Birrer, Rene dePont Christensen, Gitte-Bettina Nyvang, Susanne Malander, Maarit Anttila, Theresa L Werner, Bente Lund, Gabriel Lindahl, Sakari Hietanen, Ulla Peen, Maria Dimoula, Henrik Roed, Anja Ør Knudsen, Synnöve Staff, Anders Krog Vistisen, Line Bjørge, Johanna U Mäenpää
BACKGROUND: Platinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity. Bevacizumab and maintenance poly(ADP-ribose) polymerase (PARP) inhibitors both significantly improve efficacy versus standard therapy, primarily in terms of progression-free survival, and offer the potential for chemotherapy-free treatment. AVANOVA2 compared niraparib and bevacizumab versus niraparib alone as definitive treatment for platinum-sensitive recurrent ovarian cancer...
August 29, 2019: Lancet Oncology
https://read.qxmd.com/read/31474353/chemotherapy-free-but-not-quite-free-chemotherapy
#11
John O Schorge
No abstract text is available yet for this article.
August 29, 2019: Lancet Oncology
https://read.qxmd.com/read/31473128/the-many-roads-to-universal-health-care-in-the-usa
#12
REVIEW
Greg Jones, Hagop Kantarjian
Health-care systems in different countries have evolved along different paths, with some countries offering private insurance, some universal health care, and some a mixture between the two. In most high-income countries, health care is considered a human right and is provided universally, typically free at the point-of-care. The USA has developed a fractured for-profit system that is substantially more expensive than those of its European counterparts and delivers poorer outcomes than the health-care systems in other high-income countries, while leaving a substantial proportion of Americans without health coverage...
August 28, 2019: Lancet Oncology
https://read.qxmd.com/read/31471159/solid-organ-transplantations-in-childhood-cancer-survivors-an-unrealised-research-potential
#13
Jeanette F Winther, Ida Maria Schmidt, Emilio D Poggio
No abstract text is available yet for this article.
August 27, 2019: Lancet Oncology
https://read.qxmd.com/read/31471158/solid-organ-transplantation-after-treatment-for-childhood-cancer-a-retrospective-cohort-analysis-from-the-childhood-cancer-survivor-study
#14
Andrew C Dietz, Kristy Seidel, Wendy M Leisenring, Daniel A Mulrooney, Jean M Tersak, Richard D Glick, Cathy A Burnweit, Daniel M Green, Lisa R Diller, Susan A Smith, Rebecca M Howell, Marilyn Stovall, Gregory T Armstrong, Kevin C Oeffinger, Leslie L Robison, Amanda M Termuhlen
BACKGROUND: Serious chronic medical conditions occur in childhood cancer survivors. We aimed to investigate incidence of and risk factors for end-organ damage resulting in registration on a waiting list for or receiving a solid organ transplantation and 5-year survival following these procedures. METHODS: The Childhood Cancer Survivor Study (CCSS) is a retrospective cohort of individuals who survived at least 5 years after childhood cancer diagnosed at younger than 21 years of age, between Jan 1, 1970, and Dec 31, 1986, at one of 25 institutions in the USA...
August 27, 2019: Lancet Oncology
https://read.qxmd.com/read/31447299/tcr-gene-therapy-for-hpv-associated-epithelial-cancers
#15
Talha Khan Burki
No abstract text is available yet for this article.
August 22, 2019: Lancet Oncology
https://read.qxmd.com/read/31445962/correction-to-lancet-oncol-2019-published-online-aug-16-http-dx-doi-org-10-1016-s1470-2045-19-30413-9
#16
(no author information available yet)
No abstract text is available yet for this article.
August 21, 2019: Lancet Oncology
https://read.qxmd.com/read/31427207/azd1775-plus-chemoradiotherapy-for-pancreatic-cancer
#17
Talha Khan Burki
No abstract text is available yet for this article.
August 16, 2019: Lancet Oncology
https://read.qxmd.com/read/31427206/should-we-use-combination-therapy-for-all-advanced-renal-cell-carcinoma
#18
Giuseppe Procopio, Pierangela Sepe, Melanie Claps, Filippo de Braud, Elena Verzoni
No abstract text is available yet for this article.
August 16, 2019: Lancet Oncology
https://read.qxmd.com/read/31427205/individualised-axitinib-regimen-for-patients-with-metastatic-renal-cell-carcinoma-after-treatment-with-checkpoint-inhibitors-a-multicentre-single-arm-phase-2-study
#19
Moshe C Ornstein, Sumanta K Pal, Laura S Wood, Jackie M Tomer, Brian P Hobbs, Xuefei S Jia, Kimberly D Allman, Allison Martin, Thomas Olencki, Nancy B Davis, Timothy D Gilligan, Amir Mortazavi, W Kimryn Rathmell, Jorge A Garcia, Brian I Rini
BACKGROUND: Checkpoint inhibitor therapy is a standard of care for patients with metastatic renal cell carcinoma. Treatment options after checkpoint inhibitor therapy include vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitors, although no prospective data regarding their use in this setting exist. Axitinib is a VEGF-R inhibitor with clinical data supporting increased activity with dose titration. We aimed to investigate the activity of dose titrated axitinib in patients with metastatic renal cell carcinoma who were previously treated with checkpoint inhibitor...
August 16, 2019: Lancet Oncology
https://read.qxmd.com/read/31427204/nivolumab-plus-ipilimumab-versus-sunitinib-in-first-line-treatment-for-advanced-renal-cell-carcinoma-extended-follow-up-of-efficacy-and-safety-results-from-a-randomised-controlled-phase-3-trial
#20
Robert J Motzer, Brian I Rini, David F McDermott, Osvaldo Arén Frontera, Hans J Hammers, Michael A Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S Tykodi, Philippe Barthélémy, Raya Leibowitz-Amit, Elizabeth R Plimack, Sjoukje F Oosting, Bruce Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K Choueiri, Frede Donskov, Marc-Oliver Grimm, Howard Gurney, Daniel Y C Heng, Christian K Kollmannsberger, Michael R Harrison, Yoshihiko Tomita, Ignacio Duran, Viktor Grünwald, M Brent McHenry, Sabeen Mekan, Nizar M Tannir
BACKGROUND: In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting. METHODS: In the phase 3, randomised, controlled CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries...
August 16, 2019: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"